Feature | July 27, 2010| Mariell Jessup, M.D., professor of medicine, University of Pennsylvania School of Medicine

Novel Therapies for Advanced Heart Failure

New approaches include mechanical heart pumps, drug and gene therapies

Mariell Jessup, M.D., is a professor of medicine at the University of Pennsylvania School of Medicine.

Heart failure is a progressively debilitating disease that dramatically decreases the life expectancy and quality of life of affected patients. Nearly 5.8 million Americans are diagnosed with heart failure today, according to annual American Heart Association statistics. Heart failure contributes to more than 280,000 deaths annually, with a one-year mortality rate of approximately 20 percent, and a five-year mortality estimated at 50 percent.

Heart failure accounts for nearly 20 percent of total hospital admissions; annual hospitalizations with a primary diagnosis of heart failure in the U.S. exceed 1 million. The incidence of heart failure has not declined within the past 20 years, but the survival after onset has increased in younger patients and men. The care of patients with heart failure will lead to $39.2 billion direct and indirect costs to the United States in 2010.

Heart Failure Characteristics

Heart failure is characterized by chronic, persistent activation of the renin-angiotensin-aldosterone system as well as the sympathetic nervous system. The neurohormonal blockade of these systems has been the mainstay of heart failure therapy for more than 20 years. The implementation of angiotensin-converting enzyme (ACE) inhibitors and antiandrenergic therapies has revolutionized the treatment of heart failure to slow the progression of heart failure and improve survival. The current regimen for managing heart failure includes ACE-inhibitors, angiotensin-receptor antagonists, beta-blockers, aldosterone antagonists and diuretics; certain patients are candidates for a special pacemaker called cardiac resynchronization therapy (CRT) and others undergo coronary bypass surgery.

Pumps and Transplants

Nevertheless, heart failure is a progressive disease with no cure. As the disease progresses, existing treatment options for advanced heart failure are limited to left ventricular assist device implantation (LVAD) or cardiac transplant. Patients who have severe heart failure and primary myocardial disease, ischemic cardiomyopathy, or congenital heart disease may be considered for cardiac transplantation, but only approximately 2,000 heart transplants are done each year in the United States. Moreover, many patients depend on mechanical cardiac support devices while waiting for a transplant donor organ to become available. Additionally, many patients with end-stage heart failure are not considered for transplantation because of advanced age or other associated morbidities.

Drug and Gene Therapies

Therefore, there is a significant unmet need for novel approaches beyond the standard medical regimens currently used to treat advanced heart failure patients. The majority of current clinical studies are investigations with new approaches to reduce the mortality in acute heart failure, e.g. patient admitted to the hospital with exacerbated symptoms of heart failure. One eagerly awaited trial is the ASCEND-HF study (Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure), which enrolled 7,000 patients worldwide and is designed to evaluate whether treatment with nesiritide improves patient outcomes or heart failure symptoms compared with placebo.

Another novel approach to treat heart failure has been to target the up-regulation of sarcoplasmic reticulum (SR) Ca2+ ATPase pump (SERCA2a). SERCA2a is critical in controlling the movement of Ca2+ between the SR and cytoplasm; it regulates Ca2+ cycling and contractility in the myocardium. SERCA2a expression is significantly reduced in failing hearts, leading to abnormal Ca2+ handling and deficient contractility, a defect that could be corrected by restoring SERCA2a levels. Additionally, in animal models, cardiac energetics and electrical remodeling improved after SERCA2a gene transfer.

The first-in-human trial to utilize this novel gene therapy, CUPID (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) was recently presented in Berlin. It is noteworthy that the procedure to infuse Mydicar, a genetically targeted enzyme replacement therapy that restores SERCA2a levels via gene transfer with a recombinant adeno-associated vector (AAV), could be performed in an outpatient setting. The results showed significant improvements in clinical outcomes and symptoms in patients with advanced heart failure treated with Mydicar. These patients significantly improved their heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function. These encouraging results will have to be confirmed in larger clinical trials but may address the unmet need for novel therapeutic approaches to treat advanced heart failure.

Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)| August 30, 2016
August 30, 2016 — Medtronic plc announced results from the...
Medtronic, Micra TPS pacemaker, transcatheter pacing system, global clinical trial, one-year results, ESC 2016
News | Pacemakers| August 29, 2016
August 29, 2016 — Medtronic plc announced new long-term results from the Medtronic Micra Transcatheter Pacing System
cardiac surgery, simulation training, University of Washington, case studies

Multiple repetitions of bypass grafts on a heart, using the Ramphal simulator. Courtesy of the University of Washington in Seattle.

News | Cardiovascular Surgery| August 25, 2016
August 25, 2016 — Simulation training fo
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart| August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD)| August 24, 2016
Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical...
nanoparticles, blood clotting, internal bleeding, American Chemical Society study, Erin B. Lavik

Nanoparticles (green) help form clots in an injured liver. The researchers added color to the scanning electron microscopy image after it was taken. Image courtesy of Erin Lavik, Ph.D.

News | Hemostasis Management| August 24, 2016
August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to...
News | Heart Failure| August 23, 2016
August 23, 2016 — A new study of more than 13,000 people has found that so-called morbid obesity appears to stand alo
Jason Burdick, injectable hydrogels, heart failure, heart attack, American Chemical Society

Compared to other types of hydrogels being developed (left), a new hydrogel (right) can form crosslinks after injection into the heart, making the material stiffer and longer-lasting. Image courtesy of American Chemical Society.

News | Heart Failure| August 23, 2016
August 23, 2016 — During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells within
sleep apnea, hypertension, clinical study, Science Signaling, University of Chicago
News | Hypertension| August 22, 2016
Obstructive sleep apnea is a common cause of high blood pressure. In the Aug. 17, 2016, issue of the journal Science...
TAILOR-PCI study, antiplatelet medication, genotype, NHLBI grant
News | Antiplatelet and Anticoagulation Therapies| August 18, 2016
Researchers at the Peter Munk Cardiac Centre, Toronto, and at Mayo Clinic are leading the Tailored Antiplatelet Therapy...
Overlay Init